[HTML][HTML] Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment
JC Restrepo, D Dueñas, Z Corredor, Y Liscano - Cancers, 2023 - mdpi.com
Simple Summary In the field of non-small cell lung cancer (NSCLC), there have been
significant advancements in genomic data and bioinformatics tools, which have improved …
significant advancements in genomic data and bioinformatics tools, which have improved …
Anoverview of biomedical applications for gold nanoparticles against lung cancer
Lung cancer (LC) is the commonest class of cancer worldwide and is the reason for more
deaths than any other type. Treatment of LC using conventional therapy has some …
deaths than any other type. Treatment of LC using conventional therapy has some …
[HTML][HTML] Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug …
Breast and lung cancer are two of the most lethal forms of cancer, responsible for a
disproportionately high number of deaths worldwide. Both doctors and cancer patients …
disproportionately high number of deaths worldwide. Both doctors and cancer patients …
[HTML][HTML] An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer
Calotropin is a pharmacologically active compound isolated from milkweed plants like
Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the …
Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the …
Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment
NK Horvat, S Chocarro, O Marques, TA Bauer, R Qiu… - ACS …, 2024 - ACS Publications
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor
(TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor …
(TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor …
[HTML][HTML] The lung microbiome in COPD and lung cancer: Exploring the potential of metal-based drugs
M O'Shaughnessy, O Sheils, AM Baird - International Journal of …, 2023 - mdpi.com
Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most
prevalent and debilitating respiratory diseases worldwide, both associated with high …
prevalent and debilitating respiratory diseases worldwide, both associated with high …
[HTML][HTML] Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80%–85% of total cases and leading to millions of deaths worldwide. Drug resistance is the …
80%–85% of total cases and leading to millions of deaths worldwide. Drug resistance is the …
COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …
[HTML][HTML] PET radiomics and response to immunotherapy in lung cancer: A systematic review of the literature
L Evangelista, F Fiz, R Laudicella, F Bianconi… - Cancers, 2023 - mdpi.com
Simple Summary The present review was performed in order to provide a comprehensive
overview of the existing literature concerning the applications of positron emission …
overview of the existing literature concerning the applications of positron emission …
[HTML][HTML] Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
X Zhang, X Wang, L Hou, Z Xu, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …